Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects.

MLA

Anumolu, SivaNaga S., et al. “Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects.” Clinical Pharmacology in Drug Development, vol. 7, no. 8, Nov. 2018, pp. 829–36. EBSCOhost, https://doi.org/10.1002/cpdd.455.

APA

Anumolu, S. S., Lindgren, S., Vemula, J., Floch, D., Reynolds, C., Wallny, H., & Sun, H. (2018). Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects. Clinical Pharmacology in Drug Development, 7(8), 829–836. https://doi.org/10.1002/cpdd.455

Chicago

Anumolu, SivaNaga S., Sam Lindgren, Janardhana Vemula, David Floch, Christine Reynolds, Hans‐Joachim Wallny, and Haiying Sun. 2018. “Bioequivalence of Canakinumab Injected Subcutaneously via an Autoinjector Device or a Prefilled Safety Syringe Device in Healthy Subjects.” Clinical Pharmacology in Drug Development 7 (8): 829–36. doi:10.1002/cpdd.455.